[Skip to Content]
[Skip to Content Landing]
January 24, 1972

Diphenylhydantoin in the Treatment of Duodenal Ulcer

Author Affiliations

Livermore, Calif

JAMA. 1972;219(4):511-512. doi:10.1001/jama.1972.03190300047020

To the Editor.—  It was proposed four years ago that the induction of a state of chronic hyperglycemia by the anti-insulin effect of diazoxide should be of value in the treatment of peptic ulcers.1 The extensive side effects of diazoxide made clinical investigation of the proposal impractical.It has been found that diphenylhydantoin alters the insulin secretion following a glucose load.2 Fasting blood glucose levels remained normal as the glucose tolerance curve became elevated because of an inhibition of insulin release. This finding provides the clinician with a well-known and available drug which can test the proposal that the induction of a diabetictype glucose tolerance curve would provide the protective value which diabetes has against the development of duodenal ulcers.An activation of the glucoreceptor mechanism of the ventromedial hypothalmic nucleus has been proposed to be the neurophysiologic basis for the protection which the chronic hyperglycemia of adult-onset